Literature DB >> 24146110

Prevalence and 1-year prognosis of transient heart failure following coronary revascularization.

Marco Ambrosetti1, Raffaele Griffo, Roberto Tramarin, Francesco Fattirolli, Pier Luigi Temporelli, Pompilio Faggiano, Stefania De Feo, Anna Rita Vestri, Francesco Giallauria, Cesare Greco.   

Abstract

The occurrence of heart failure during the whole pre-discharge course of coronary revascularization, as far as its influence on subsequent prognosis, is poorly understood. The present study examined the effect of transient heart failure (THF) developing in the acute and rehabilitative phase on survival after coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI). Patients in the Italian survey on cardiac rehabilitation and secondary prevention after cardiac revascularization (ICAROS) were analyzed for THF, the latter being defined either as signs and symptoms consistent with decompensation or cardiogenic shock. ICAROS was a prospective, multicenter registry of 1,262 consecutive patients discharged from 62 cardiac rehabilitation (CR) facilities, providing data on risk factors, lifestyle habits, drug treatments, and major cardiovascular events (MACE) during a 1-year follow-up. Records were linked to the official website of the Italian Association of Cardiovascular Prevention and Rehabilitation (GICR-IACPR). The overall prevalence of pre-discharge THF was 7.6%, with 69.8% of cases in acute wards, 22.9% during CR, and 7.3% in both settings. THF affected more frequently patients with chronic cardiac condition (42.7 vs. 30.6%; p < 0.05), age ≥75 years (33.3 vs. 23.1%; p < 0.005), COPD (19.8 vs. 12.3%; p < 0.05), and chronic kidney disease (17.7 vs. 7%; p < 0.001). After discharge, THF patients showed good maintenance rates of RAAS modulators (90.6%) and beta-blockers (83.3%), while statin therapy significantly decreased from 81.3 to 64.6% (p < 0.05). The pursuit of secondary prevention targets, as far as self-reported drug adherence, was not different among groups. Patients with THF had increased 1-year mortality (8.3 vs. 1.6%, p < 0.001). Moreover, THF independently predicted adverse outcome with OR for recurrent events (mainly further episodes of decompensation) of 2.4 (CI 1.4-4.3). Patients who experienced THF after coronary revascularization had increased post-discharge mortality and cardiovascular events. Hemodynamic instability, rather than recurrent myocardial ischemia, seems to be linked with worse prognosis.

Entities:  

Mesh:

Year:  2013        PMID: 24146110     DOI: 10.1007/s11739-013-1006-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  15 in total

1.  Baseline clinical and angiographic variables associated with long-term outcome after successful intracoronary stent implantation.

Authors:  V Mathew; D E Grill; C G Scott; K N Garratt; D R Holmes
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

2.  Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey.

Authors:  Raffaele Griffo; Marco Ambrosetti; Roberto Tramarin; Francesco Fattirolli; Pier Luigi Temporelli; Anna Rita Vestri; Stefania De Feo; Luigi Tavazzi
Journal:  Int J Cardiol       Date:  2012-05-08       Impact factor: 4.164

3.  Long term prognosis after CABG in relation to preoperative left ventricular ejection fraction.

Authors:  J Herlitz; B W Karlson; H Sjöland; G Brandrup-Wognsen; M Haglid; T Karlsson; K Caidahl
Journal:  Int J Cardiol       Date:  2000-01-15       Impact factor: 4.164

4.  Twenty-year survival after coronary artery surgery: an institutional perspective from Emory University.

Authors:  William S Weintraub; Stephen D Clements; L Van-Thomas Crisco; Robert A Guyton; Joseph M Craver; Ellis L Jones; Charles R Hatcher
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

5.  Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study.

Authors:  Antonio Di Chiara; Claudio Fresco; Stefano Savonitto; Cesare Greco; Donata Lucci; Lucio Gonzini; Antonio Mafrici; Filippo Ottani; Leonardo Bolognese; Stefano De Servi; Alessandro Boccanelli; Aldo P Maggioni; Francesco Chiarella
Journal:  Eur Heart J       Date:  2005-10-11       Impact factor: 29.983

6.  The prognostic role of chronic obstructive pulmonary disease in ST-elevation myocardial infarction after primary angioplasty.

Authors:  Chiara Lazzeri; Serafina Valente; Paola Attanà; Marco Chiostri; Claudio Picariello; Gian Franco Gensini
Journal:  Eur J Prev Cardiol       Date:  2011-10-24       Impact factor: 7.804

Review 7.  Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation.

Authors:  Massimo Francesco Piepoli; Ugo Corrà; Werner Benzer; Birna Bjarnason-Wehrens; Paul Dendale; Dan Gaita; Hannah McGee; Miguel Mendes; Josef Niebauer; Ann-Dorthe Olsen Zwisler; Jean-Paul Schmid
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2010-02

8.  The timing of development and subsequent clinical course of heart failure after a myocardial infarction.

Authors:  Azam Torabi; John G F Cleland; Nasrin K Khan; Puan H Loh; Andrew L Clark; Farqad Alamgir; John L Caplin; Alan S Rigby; Kevin Goode
Journal:  Eur Heart J       Date:  2008-03-19       Impact factor: 29.983

9.  Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions <or=40%, 41% to 49%, and >or=50% having percutaneous coronary revascularization.

Authors:  Paul C Keelan; Janet M Johnston; Tulay Koru-Sengul; Katherine M Detre; David O Williams; James Slater; Peter C Block; David R Holmes
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

10.  Self-reported Morisky score for identifying nonadherence with cardiovascular medications.

Authors:  Stephen J Shalansky; Adrian R Levy; Andrew P Ignaszewski
Journal:  Ann Pharmacother       Date:  2004-07-06       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.